Pharma Royalty deal update

Published May 1, 2003 12:00 AM EDT 1 Min Read

Credit Suisse First Boston is the lead manager on Royalty Pharma’s pending pharmaceutical patent-backed deal, currently in the marketing stages. This transaction, a follow-up to the Zerit-backed BioPharma Royalty Trust I, is said to be backed by a broader pool of patents. WestLB London agented the first transaction (see ASR 3/24).

For reprint and licensing requests for this article, click here.

Uncategorized

More From Asset Securitization Report

Securitization

KKR leads $500 million debt deal for HarbourView music royalties

KKR has been rapidly seeking to expand its asset-based financing business, which has about $48 billion in assets since starting up in 2016.

March 13

Esoteric ABS

DRI Capital to issue another $100M of pharmaceutical royalty ABS

The bonds will be collateralized by payments from 15 royalty streams on 14 patent-protected drugs and technologies and will rank pari passu with securities issued from the same master trust in 2017.

By Glen Fest

November 28

ABS

DRI Returns with $150M of Drug Royalty Cashflow ABS

DRI Capital is marketing another $150 million of bonds backed by royalties flowing from pharmaceutical patents on established drugs, according to Kroll Bond Rating Agency.

May 22

DRI Capital Plans $450M Drug Royalty Deal

DRI Capital, a Canadian healthcare investment firm, is in the market with a $450 million securitization of drug royalty payments, according to a presale report published by Standard & Poors.

June 18

ABS

Moody’s Withdraws DRI Capital’s Pharma Deal Rating

Moody’s Investors Service has just withdrawn its provisional rating of ‘Baa2 (sf)’ on the secured notes, Series 2011-1 that were to be issued by Drug Royalty LP 1, a subsidiary of Toronto-based DRI Capital. Credit Suisse is lead managing the deal. The $200 million securitization was backed by 18 drug royalty streams generated from the global sales of 14 drugs. […]

November 15